Modulation of the gamma-aminobutyric acid type A receptor by the antiepileptic drugs carbamazepine and phenytoin

P Granger, B Biton, C Faure, X Vige, H Depoortere, D Graham, SZ Langer, B Scatton and P Avenet

Synthelabo Recherche, Preclinical Research Department, Bagneux, France.

We report here that carbamazepine and phenytoin, two widely used antiepileptic drugs, potentiate gamma-aminobutyric acid (GABA)-induced Cl- currents in human embryonic kidney cells transiently expressing the alpha 1 beta 2 gamma 2 subtype of the GABAA receptor and in cultured rat cortical neurons. In cortical neuron recordings, the current induced by 1 microM GABA was enhanced by carbamazepine and phenytoin with EC50 values of 24.5 nM and 19.6 nM and maximal potentiations of 45.6% and 90%, respectively. The potentiation by these compounds was dependent upon the concentration of GABA, suggesting an allosteric modulation of the receptor, but was not antagonized by the benzodiazepine (omega) modulatory site antagonist flumazenil. Carbamazepine and phenytoin did not modify GABA-induced currents in human embryonic kidney cells transiently expressing binary alpha 1 beta 2 recombinant GABAA receptors. The alpha 1 beta 2 recombinant is known to possess functional barbiturate, steroid, and picrotoxin sites, indicating that these sites are not involved in the modulatory effects of carbamazepine and phenytoin. When tested in cells containing recombinant alpha 1 beta 2 gamma 2, alpha 3 beta 2 gamma 2, or alpha 5 beta 2 gamma 2 GABAA receptors, carbamazepine and phenytoin potentiated the GABA-induced current only in those cells expressing the alpha 1 beta 2 gamma 2 receptor subtype. This indicates that the nature of the alpha subunit isoform plays a critical role in determining the carbamazepine/phenytoin pharmacophore. Our results therefore illustrate the existence of one or more new allosteric regulatory sites for carbamazepine and phenytoin on the GABAA receptor. These sites could be implicated in the known anticonvulsant properties of these drugs and thus may offer new targets in the search for novel antiepileptic drugs.

Volume 47, Issue 6, pp. 1189-1196, 06/01/1995
Copyright © 1995 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				L. Liu, T. Zheng, M. J. Morris, C. Wallengren, A. L. Clarke, C. A. Reid, S. Petrou, and T. J. O'Brien The Mechanism of Carbamazepine Aggravation of Absence Seizures J. Pharmacol. Exp. Ther., November 1, 2006; 319(2): 790 - 798. [Abstract] [Full Text] [PDF]

				L. D. Snell, D. J. Claffey, J. A. Ruth, C. F. Valenzuela, R. Cardoso, Z. Wang, S. R. Levinson, W. A. Sather, A. V. Williamson, N. C. Ingersoll, et al. Novel Structure Having Antagonist Actions at Both the Glycine Site of the N-Methyl-D-Aspartate Receptor and Neuronal Voltage-Sensitive Sodium Channels: Biochemical, Electrophysiological, and Behavioral Characterization J. Pharmacol. Exp. Ther., January 1, 2000; 292(1): 215 - 227. [Abstract] [Full Text]